Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal of this study was to assess th
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients
✍ Scribed by Ezequiel Ridruejo; Raúl Adrover; Daniel Cocozzella; María Virgina Reggiardo; Nora Fernández
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 495 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocio´n Cien-tı´fica y Tecnolo´gica).
📜 SIMILAR VOLUMES
We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pe-gIFN-␣) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders. Seventeen pat
## Abstract Lung toxicity related to interferon (IFN) alpha typically takes a form of interstitial pneumonitis, granulomatous inflammation, or organizing pneumonia. We report a case of a 52‐year‐old woman, who developed pneumonitis with exudative, lymphocytic‐predominant pleural effusion following
## Abstract The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and ca